Literature DB >> 10596968

Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.

T Inukai1, K Takanashi, K Takebayashi, Y Fujiwara, K Tayama, Y Takemura.   

Abstract

The expression and synthesis of insulin-like growth factor-1 (IGF-I) and IGF-binding protein-3 (IGFBP-3) are regulated by various hormones and nutritional conditions. We evaluated the effects of thyroid hormones on serum levels of IGF-I and IGFBP-3 levels in patients with autoimmune thyroid diseases including 54 patients with Graves' disease and 17 patients with Hashimoto's thyroiditis, and in 32 healthy age-matched control subjects. Patients were subdivided into hyperthyroid, euthyroid and hypothyroid groups that were untreated, or were treated with methylmercaptoimidazole (MMI) or L-thyroxine (L-T4). Serum levels of growth hormone (GH), IGF-I and IGFBP-3 were determined by radioimmunoassay. Serum GH levels did not differ significantly between the hyperthyroid and the age-matched euthyroid patients with Graves' disease. The serum levels of IGF-I and IGFBP-3 showed a significant positive correlation in the patients (R=0.616, P<0.001). The levels of both IGF-I and IFGBP-3 were significantly higher in the hyperthyroid patients with Graves' disease or in those with Hashimoto's thyroiditis induced by excess L-T4 administration than in control subjects. Patients with hypothyroid Graves' disease induced by the excess administration of MMI showed significantly lower IGFBP-3 levels as compared to those in healthy controls (P<0.05). Levels of IGFBP-3, but not IGF-I levels, showed a significant positive correlation with the levels of free T4 and free T3. In Graves' disease, levels of TPOAb, but not of TRAb, showed a significant positive correlation with IGFBP-3. We conclude that in patients with autoimmune thyroid diseases, thyroid hormone modulates the synthesis and/or the secretion of IGF-I and IGFBP-3, and this function is not mediated by GH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596968     DOI: 10.1055/s-2007-978798

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

1.  Sensitivity of supplementation of thyroid hormone on treatment of idiopathic short-stature children during therapy with recombinant human growth hormone.

Authors:  Wei Wang; Shuqin Jiang; Zhirui Cui; Xiangyang Luo; Lingli Shi; Heli Zheng
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

2.  A genome-wide DNA methylation analysis in peripheral blood from patients identifies risk loci associated with Graves' orbitopathy.

Authors:  Z Xin; L Hua; T-T Shi; X Tuo; F-Y Yang; Y Li; X Cao; J-K Yang
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

3.  Kidney growth in children with congenital hypothyroidism.

Authors:  Mehmet Bülbül; Semra Cetinkaya; Seçil Ekşioğlu; Serdar Ozkasap; Tayfur Giniş
Journal:  Pediatr Nephrol       Date:  2008-09-25       Impact factor: 3.714

4.  Thyroid function in children with growth hormone (GH) deficiency during the initial phase of GH replacement therapy - clinical implications.

Authors:  Joanna Smyczynska; Maciej Hilczer; Renata Stawerska; Andrzej Lewinski
Journal:  Thyroid Res       Date:  2010-03-22

5.  Do IGF-I concentrations better reflect growth hormone (GH) action in children with short stature than the results of GH stimulating tests? Evidence from the simultaneous assessment of thyroid function.

Authors:  Joanna Smyczyńska; Renata Stawerska; Andrzej Lewiński; Maciej Hilczer
Journal:  Thyroid Res       Date:  2011-01-13

6.  Thyroid function in children with growth hormone deficiency during long-term growth hormone replacement therapy.

Authors:  Ewelina Witkowska-Sędek; Ada Borowiec; Anna Majcher; Maria Sobol; Małgorzata Rumińska; Beata Pyrżak
Journal:  Cent Eur J Immunol       Date:  2018-10-30       Impact factor: 2.085

7.  Serum levels of insulin-like growth factor 1 are negatively associated with log transformation of thyroid-stimulating hormone in Graves' disease patients with hyperthyroidism or subjects with euthyroidism: A prospective observational study.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chiao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

8.  The Prospective Association Between Plasma Concentrations of Cellular Growth Factors and Risk of Heart Failure Mortality in Japanese Population.

Authors:  Ehab S Eshak; Koutatsu Maruyama; Hiroyasu Iso; Akiko Tamakoshi
Journal:  J Epidemiol       Date:  2018-08-04       Impact factor: 3.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.